Results 181 to 190 of about 231,595 (267)

STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities. [PDF]

Theranostics
Gonçalves LCP, Rastoin O, Morozova V, Buzet C, Bennetot A, Pagès G, Ronco C, Dufies M.   +7 more
europepmc   +1 more source

Cuproptosis and Mitophagy Mediated by the THUMPD1/IGF2R‐Dependent Suppression of AKT and Activation of AMPK Signaling Suppress Lung Adenocarcinoma Progression

Advanced Science, EarlyView.
THUMPD1 drives a tumor‐suppressive signaling cascade in lung adenocarcinoma by promoting IGF2R expression. IGF2R associates with PPP2R1A to suppress AKT and activate AMPK, leading to SLC31A1 upregulation and copper accumulation. Elevated copper disrupts mitochondrial metabolism and induces excessive mitophagy, thereby restraining tumor growth and ...
Kai Wu, Bo Qin, Zhuoyu Gu, Weizheng Ding, Xiaoming Chen, Kaishang Zhang, Yujin Qiao, Shuang Yuan, Song Zhao, Xiangnan Li, Peng Zhang   +10 more
wiley   +1 more source

Meta-cancer phosphoproteomic analysis unveils association of Tau phosphosites with DNA damage response. [PDF]

Front Syst Biol
Poojari TR, Dcunha L, Mahin A, Gopalakrishnan AP, Ahmed M, Sekhar PS, Ummar S, John L, Modi PK, Soman S, Raju R, Palollathil A.   +11 more
europepmc   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

The Role of Protein Kinases in the Management of Oncological Diseases by Acting on Ferroptotic Pathways. [PDF]

Int J Mol Sci
Folgiero V, Caforio M.
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Non-receptor tyrosine kinase signaling pathways and therapeutic implications. [PDF]

Signal Transduct Target Ther
Hossain MDA, Marques Cuoco C, Sodaye SH, Beci J, Belkas K.   +4 more
europepmc   +1 more source

Combining Fret and Super‐Resolution Microscopy Reveals Kinase Activation and Mitochondrial Activity at the Nanoscale

Advanced Science, EarlyView.
BioSenSRRF is an open‐source workflow that combines conventional FRET biosensors with SRRF reconstruction to generate sub‐diffraction FRET index maps on standard microscopes. The pipeline integrates automated image registration, SRRF reconstruction, quantitative FRET index calculation, and random line‐based hotspot analysis to uncover AURKA‐dependent ...
Nicolas Y. Jolivet, Pierre‐Jean Desmaison, Xavier Pinson, Arthur Masson, Olivier Delalande, Giulia Bertolin   +5 more
wiley   +1 more source

Targeting DYRKs in Cardiovascular Diseases: From Biological Mechanisms to Therapeutic Translation. [PDF]

Int J Mol Sci
Jiang L, Peng S, Ma J, Liu T, Long X, Li L, Wu H.   +6 more
europepmc   +1 more source

Targeting METTL3 Attenuates Thyroid Inflammatory Injury by Restoring Th17/Treg Balance through a YTHDC2‐m6A‐Dependent KDR/VEGFA Loop

Advanced Science, EarlyView.
METTL3‐mediated m6A modification stabilizes KDR/Kdr mRNA through YTHDC2, amplifying the VEGFA‐KDR feedback loop and disturbing Th17/Treg balance. This pathway promotes persistent inflammation and tissue damage in patients with AIT, and inhibiting the METTL3‐KDR axis effectively disrupts this circuit, alleviating thyroid tissue injury and disease ...
Qingyi Hu, Huan Liu, Anwen Ren, Zimei Tang, Jie Tan, Wen Yang, Jie Ming, Tao Huang   +7 more
wiley   +1 more source